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Abstract As shown by genomic studies, colorectal cancer
(CRC) is a highly heterogeneous disease, where copy number
alterations (CNAs) may greatly vary among different patients.
To explore whether CNAs may be present also in histologi-
cally normal tissues from patients affected by CRC, we per-
formed CGH + SNP Microarray on 15 paired tumoral and
normal samples. Here, we report for the first time the occur-
rence of CNAs as a common feature of the histologically
normal tissue from CRC patients, particularly CNAs affecting
different oncogenes and tumor-suppressor genes, including
some not previously reported in CRC and others known as
being involved in tumor progression. Moreover, from the
comparison of normal vs paired tumoral tissue, we were able
to identify three groups: samples with an increased number of
CNAs in tumoral vs normal tissue, samples with a similar
number of CNAs in both tissues, and samples with a decrease
of CNAs in tumoral vs normal tissue, whichmay be likely due
to a selection of the cell population within the tumor. In con-
clusion, our approach allowed us to uncover for the first time
an unexpected frequency of genetic alteration in normal
tissue, suggesting that tumorigenic genetic lesions are already
present in histologically normal colonic tissue and that the use
in array comparative genomic hybridization (CGH) studies of
normal samples as reference for the paired tumors can lead to
misrepresented genomic data, which may be incomplete or
limited, especially if used for the research of target molecules
for personalized therapy and for the possible correlation with
clinical outcome.
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CGH comparative genomic hybridization
CIMP CpG island methylator phenotype
CIN chromosomal instability
CNA copy number alteration
CRC colorectal cancer
LOH loss of heterozygosity
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Introduction
Colorectal cancer (CRC) is a heterogeneous disease defined
by distinct molecular signatures, distinct pathological features,
and distinct natural histories. There are at least three major
molecular pathways to CRC genetically identified by chromo-
somal instability (CIN), microsatellite instability (MSI), and
the CpG island methylator phenotype (CIMP). The CIN path-
way is characterized by structural rearrangements, amplifica-
tions, deletions, and copy number alterations (CNAs). The
MSI pathway’s main feature is the mutation or aberrant
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methylation of DNA mismatch repair genes, whereas in the
CIMP pathway, excessive promoter methylation occurs [1].
Several groups have studied chromosomal aberrations in
CRC by means of array comparative genomic hybridization
(array-CGH) being the most common reported aberration
gains on chromosomes 20q, 13q, 7p, and 8q and losses on
chromosomes 18q, 17p, and 8p [2–4].
More recently, the increase in genomic studies lead to the
identification of copy number aberrations linked to adenoma-
carcinoma progression or linked to metastases. For example,
gains on chromosomes 7p, 13q, and 20p/q and loss on 18q
were reported as early DNA alterations [5]. Gains at 8q, 13q,
and 20p/q and losses at 8p, 15p, 17p, and 18q were shown to
be significantly changed between adenomas and stage I carci-
nomas [6].
Copy numbers of 3q, 10q, 11q, and 15q and Xp regions
were reported as being linked to node metastases [7],
whereas gains at chromosomes 1q, 6p21, 10p, and 17q21
and loss at chromosome 8p12 occurred more frequently in
metastases than in primary tumors [6]. In addition, it has
been investigated if shared CNAs may contain candidate
genes for targeted therapy [8] or may have a possible cor-
relation with clinical outcome. For example, losses at
16p13.3 and 19q13.3 were correlated with negative out-
come, with a strong association with early relapse and
death [6]. Also, loss of 8p23-p21 occurred more often in
patients with a poor prognosis [9].
While several array-CGH analyses have been performed
on colonic tumoral tissues, genetic analysis of histologically
normal tissues is still lacking. In fact, in all the studies re-
ported so far, colon normal tissues were used individually or
pooled as reference for tumor but were never analyzed in
itself, comparing different individual samples. Only one re-
port shows small gains at 19q and 20q in pooled normal
tissues [9]. Notably, in 10–20 % of CRC patients undergo-
ing surgery with curative intent, a local recurrence succes-
sively occurs [10], suggesting that tumorigenic genetic le-
sions may be already present also when the colonic tissue
appears histologically normal. If this was the case, the use in
array-CGH studies of normal samples as reference for the
corresponding tumors would lead to misrepresented geno-
mic data, due to the loss of identical CNAs between the two
samples. An additional consequence would also be that
even available array-CGH data may be incomplete or limit-
ed, both for the research of target molecules for personalized
therapy and for the possible correlation with clinical
outcome.
To address this very important issue, we analyzed by CGH
+ SNP Microarray the genome of 15 paired tumoral and his-
tologically normal colonic tissues. Here, we report for the first
time the occurrence of CNAs as a common feature of the




A total of 15 paired samples of sporadic tumoral and sur-
rounding histologically normal tissue (taken at a distance of
10 cm from the tumor) were obtained from patients undergo-
ing surgery in three different centers. University of Milano-
Bicocca Ethics Committee approval and written informed
consent was obtained before tissue collection, but blood sam-
ples were not included. Staging and grading were done ac-
cording to the World Health Organization Consensus
Classification.
Array-CGH
For the array-CGH analysis, genomic DNA was extracted
from fresh biopsies after enzymatic digestion with trypsin/
EDTA 1X (EuroClone) at 37 °C for 60–90 min and proteinase
K (Roche) at 37 °C for 30 min and purified using phenol/
chloroform (Carlo Erba). Sample preparation, slide hybridiza-
tion, and analysis were performed using CytoSure ISCA +
SNP array 4x180K and CytoSure Cancer + SNP array
4x180K (Oxford Gene Technology, CGH and SNP probes
provided on the same slide) according to the manufacturer’s
instructions. Sex-matched commercial DNA samples
(Promega) were used as reference DNA for normal samples,
while normal paratumoral DNAs were used as reference for
tumoral tissues. Tumoral samples were checked for the pres-
ence of at least 70 % of tumor epithelial cells by an expert
pathologist on a slide of neighboring tissue. We collected
fresh, consecutive, and unselected samples to perform
array-CGH immediately after the histological diagnosis, with-
out other information.
DNA extraction from normal and tumoral paired fresh
samples received from the different hospitals was carried out
in our laboratory, where all the DNA quality control checks
required by array-CGH protocol were performed at every step:
after the purification with phenol/chloroform, after enzymatic
digestion, and after labeling. No differences were observed
among samples from different hospitals. All samples showed
a suitable quality for the protocol standards.
Briefly, the test and reference DNAs were denatured and
labeled by random priming with Cy3-dUTP and Cy5-dUTP,
respectively. Then, both samples were concentrated and then
coupled according to the efficiency of labeling (only for com-
mercial and normal DNA). Following probe denaturation and
preannealing with Cot-1 DNA, hybridization was performed
at 65 °C with rotation for 40 h at 20 rpm.
The arrays were scanned at 2-μm resolution using an
Agilent microarray scanner and analyzed using CytoSure
Interpret Software.
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Experiments showed excellent DLRS values (mean 0.18,
range 0.15–0.31), so mosaic CNAs were also included in the
study with a good confidence. To calculate the estimated per-
centage of mosaicism, we used the formula determined by
Cheung et al. [11].
We applied a filtering option of a minimum of four aberrant
consecutive probes and a minimum absolute average log2
ratio that differs among all samples and depends to DLRS
values, so it is related to the quality of experiment. In partic-
ular, non mosaic gains and losses are identified by standard
log2 ratio values for all samples: values over 0.6, which cor-
respond to three copies, identify non-mosaic gains; values
under −1, which correspond to 1 copy, identify non-mosaic
losses. Accordingly, log2 ratio values for mosaic gains range
between the DLRS value and 0.6 and for mosaic losses be-
tween the DLRS value and −1. The loss of heterozygosity
(LOH) regions were selected with a score above 200 by
CytoSure Interpret Software.
Gene ontology analysis
To identify the most represented ontology classes among the
genes contained in normal gained regions, we used the GOstat
software [12]. The GO terms in the output are linked to a
visualization tool for the GO hierarchy (AmiGO, the Gene
Ontology database, version 1.8).
Results
General data
We performed array-CGH analysis on 15 paired tumoral and
histologically normal samples obtained from patients affected
by CRC. Males and females were equally represented: eight
females and seven males. The mean age was 71.9 (range 52–
85 years) and the majority of samples were adenocarcinomas
(12 of 15). Tumors were mostly located in the ascending colon
and hepatic flexure (40 %), following by sigmoid colon, de-
scending colon, and rectum. The samples were almost equally
distributed between stage II and stage III and between grade 2
and grade 3 (Table 1).
Analysis of normal tissues
The CNAs of histologically normal samples greatly varied
among different patients ranging from 26 to 345 (average
160). Comparing the number of CNAs detected in normal
tissues vs reference DNA, a statistically significant difference
was evident between stage II and stage III samples (p < 0.05,
Student’s t test, staging is referred to the corresponding tumor
sample), which was not present when samples were divided
by grade or by tumor location (data not shown).
CNA distribution within chromosomes was also variable,
being the chromosomes with a higher average number of
CNAs chr2, chr17, and chr1 (Fig. 1a). Calculating the density
of CNAs over the chromosome length, chr17, chr19, chr21,
and chr22 turned out as those with greater density, whereas
chr13 and chr18 where those with fewer alterations (Fig. 1b).
The same results were obtained calculating the density over
the number of probes present on each chromosome (Fig. 1c).
Due to the high number of CNAs detected in the normal
samples, we choose to further analyze those shared by at least
7 out of 15 cases. Following this approach, 90 CNAs were
selected, mainly distributed on chromosomes 2 (8 CNAs), X
(7 CNAs), 5, 7, 8, 10, and 17 (6 CNAs each). No shared CNAs
were found on chromosomes 6, 18, and Y (Table S1). Notably,
the majority of CNAs were mosaic copy number alterations.
Shared CNAs could be divided into three types: (1) CNAs
containing at least one tumor-associated gene (Fig. 2), (2)
CNAs not affecting known tumor-associated genes, (3)
large-sized CNAs (large aberrations) involving several genes.
Interestingly, 13/15 samples showed a gain on 21q22.12 con-
taining RUNX1, a gene involved in translocations in different
types of leukemia and generally considered a tumor suppressor
in myeloid neoplasms. Among the CNAs shared by the great
majority of the samples, there are also two gains that were re-
ported as polymorphic in the Database of Genomic Variants
(DGV), hence devoid of a pathogenetic role: a non-mosaic gain,
localized on 14q32.33, containing KIAA0125 and ADAM6
genes, shared by 14/15 samples and one containing IGKV pres-
ent in 12 cases. A large group of gains, shared by approximately
half of the samples, included the oncogenes MPL (1p34.2, 7
samples), TRIB2 (2p24.3, 8 samples), ERBB2 (17q12, 7 sam-
ples), and ARAF (Xp11.23, 7 samples) and other genes impli-
cated in oncogenesis such as TERT (5p15.33, 8 samples),
FGFR1 (8p11.23-p11.22, 7 samples), and RECQL4 (8q24.3, 9
samples). Tumor suppressor genes such as PTCH1, DAB2IP,
and WT1, usually lost in tumors, were also included in the
gained regions of approximately half of the samples. Also,
RET (10q11.21, seven samples),CTSB (8p23.1, seven samples),
andCDKN2A (9p21.3, seven samples) copy number gains were
found, but they are included in DGVas benign variants.
To note, the only two normal samples, whose paired tumor-
al tissue has an undifferentiated histotype, shared two gains
not present in any other normal sample, one on chromosome
8q24.21 including MYC oncogene and one on chromosome
Xp21.3 containing the MAGEB18, MAGEB6, and MAGEB5
genes.
The copy number gain of ERBB2, RECQL4, and MYC
oncogene and MAGEB family has been frequently reported
in colorectal carcinoma, as shown in a recent review [13].
Twelve shared CNAs fell into the second group that does
not contain any known tumor-associated gene.
Next, in order to find statistically overrepresented GO cat-
egories among the genes included in the gained regions
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Fig. 1 Copy number alterations
in normal samples. Chromosome
distribution of copy number
alterations in normal samples (a)
and CNA frequency over the
chromosome length (b) and over
the number of probes (c). Gains
and losses are mixed together to
assess which chromosomes were
most affected by CNAs
Table 1 Clinicopathologic
characteristics of tumoral samples Patient Age Sex Histotype Location Stage Grade
1 80 F Adenocarcinoma Sigmoid IIA 2
2 71 F Adenocarcinoma Ascending colon and hepatic flexure III 3
3 80 M Undifferentiated
carcinoma
Ascending colon and hepatic flexure IIIA 3
4 59 F Adenocarcinoma Ascending colon and hepatic flexure II 2
5 79 F Adenocarcinoma Ileocecal valve IIIC 2
6 69 F Adenocarcinoma Ascending colon and hepatic flexure II 3
7 85 M Adenocarcinoma Ascending colon and hepatic flexure III 3
8 69 F Adenocarcinoma Sigmoid IV 3
9 71 M Adenocarcinoma Cecum IIA 2
10 77 M Mucinous carcinoma Rectum IVA nd
11 81 M Adenocarcinoma Sigmoid IIA 2
12 85 F Adenocarcinoma Descending colon and splenic
flexure
II 2
13 58 M Adenocarcinoma Rectum IIIC 3
14 52 M Adenocarcinoma Descending colon and splenic
flexure
III 2
15 62 F Undifferentiated
carcinoma
Ascending colon and hepatic flexure IIA 4
Histotype, location, stage and grade are indicated
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(Fig. S1), we performed a gene ontology analysis, using the
GOstat software. Table S2 shows statistically significant
(p < 0.05) GO terms. The most represented category was
regulation of the biological process which comprises regula-
tion of transcription, of gene expression, of growth, of apo-
ptosis and of cellular metabolic process.
Analysis of tumoral tissues
Tumoral samples, tested against the paired normal sample,
showed a lower average but a more widespread ranging of
CNAs (5 to 549, average 106). Comparing the number of
CNAs in different tumoral samples (excluding the two sam-
ples with a higher number of CNAs), a statistically significant
difference was evident between stage II and stage III samples
and between stage IV and stage III samples (p < 0.05,
Student’s t test), but it was not present when the samples were
divided by grade or by tumor location (data not shown). CNA
distribution within the chromosomes was variable, being
chr17, chr1, and chr2 those with a higher average number of
CNAs (Fig. 3a). Chromosomes with the greatest density of
CNAs over the chromosome length were chr17, chr19, and
chr22, whereas chr8 and chr13 were those with the fewest
alterations (Fig. 3b). The same results were obtained calculat-
ing the density over the number of probes present on each
chromosome, except for Y showing a strong frequency in-
crease, probably due to the small number of probes on this
chromosome (Fig. 3c).
Also for tumoral samples, we choose to further analyze
CNAs shared by at least 7 out of 15 cases: this led to the
selection of 12 CNAs, mainly consisting in large aberrations
encompassing several genes (Fig. 4); notably, the majority
were mosaic CNAs. The most shared CNA (10/15) was a gain
of 20q11.21-q11.22, which in eight samples was larger and
extended from 20q11.21 to 20q13.33. The secondmost shared
CNAwas located in 20p13 and was found in 9/15 samples. To
note, the only sample with mucinous histotype had an oppo-
site CNA, with a loss of 20p and 20q regions. Among the most
shared CNAs, twowere characterized by being in loss in some
samples and in gain in others: a CNA on chromosome 10
containing RET oncogene, shared by eight samples and a
CNA with APP, shared by seven samples. Finally, in seven
samples, we found on chromosome 7 a shared gained region
containing several genes.
Comparison between histologically normal and tumoral
tissues
Copy number alterations
We divided CNAs into unique or shared between paired nor-
mal and tumoral tissue as listed in Table 2. The number of
shared CNAs was not identical because some large CNAs can
contain smaller CNAs in the same region. Using normal tissue
as a reference for the corresponding tumor, alterations that are
equal between both tissues are not detectable by array-CGH,
since the competition for the oligonucleotide probes is the
same and only different ones can be identified. As a conse-
quence, CNAs present in both normal and tumoral samples
Fig. 2 Distribution of shared CNAs in histologically normal tissues.
Graphic representation of copy number alterations, detected by CGH,
shared by at least 7 out of 15 normal tissues. Shared CNAs could be
divided into three types: CNAs containing at least one tumor-associated
gene (blue); CNAs not affecting known tumor-associated genes (purple);
large-sized CNAs involving several genes (green)
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(shared CNAs) must be more amplified in the latter; other-
wise, they would have been scored as disomic.
Excluding Bmasked^ CNAs, our results highlighted three
groups: (1) samples with an increased number of CNAs in
tumoral vs normal tissue (five cases); (2) samples with a sim-
ilar number of CNAs in both tissues (two cases); (3) samples
with a decrease of CNAs in tumoral vs normal tissue (eight
cases). Samples falling in the first group, such as those from
Fig. 3 Copy number alterations
in tumoral samples. Chromosome
distribution of copy number
alterations in tumoral samples (a)
and CNA frequency over the
chromosome length (b) and over
the number of probes (c). Gains
and losses are mixed together to
assess which chromosomes were
most affected by CNAs
Fig. 4 Distribution of shared CNAs in tumoral tissues. Graphic
representation of copy number alterations, detected by CGH, shared by
at least 7 out of 15 tumoral tissues. Shared CNAs could be divided into
three types: CNAs containing at least one tumor-associated gene (blue);
CNAs not affecting known tumor-associated genes (purple); large-sized
CNAs involving several genes (green)
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patients 2 and 6, are characterized by increased genomic in-
stability. Instead, in samples of the third group, a decreased
genomic instability was evident (for example patients 3, 12,
and 14), probably due to a selection of the cell population in
tumoral tissues. From this last group, we analyzed CNAs
present only in the tumoral tissue (unique) and disomic in
the paired normal sample, assuming a possible role in tumor
progression; only two CNAs shared by at least three of eight
samples met this parameter: one comprising RBFOX1 gene
and the other comprising PCDH11Y gene. RBFOX1 copy
number gain and loss are reported in DGVas benign variants.
Finally, we analyzed for all samples the CNAs shared be-
tween normal and tumoral samples. Eight gains were shared
by at least three samples, localized in the following: 2p24.3
(TRIB2 gene), 3q29 (MFI2), 10q11.21 (RET), 12q13.12
(WNT1, DDN, PRKAG1), 21q22.12 (RUNX1), Xq21.1
(BRWD3), Xq25 (GRIA3), Xq25 (XIAP). Most of these genes
were reported to be involved in several types of cancer
(Table 3). Gene ontology analysis showed different significant
ontology classes but includes no more than one gene.
Aneuploidies
By using the Cytosure software (that gives the possibility to
obtain a graphical representation of averages and standard
deviations of all log2 ratios of chromosome probes), we eval-
uated the distribution of the chromosome probes and identi-
fied the aneuploidies, also at mosaic (Fig. S2).
The most frequent aneuploidies in tumoral samples were as
follows: loss of 18q (10/15 cases, all mosaic); loss of whole
chromosome 18 (8 cases, all mosaic); gain of 20q (8 cases, 5
non-mosaic, and 3 mosaic); gain of whole chromosome 20 (7
cases, 3 non-mosaic, and 4 mosaic); gain of 8q (7 cases, 3 non-
mosaic, and 4 mosaic); gain of 13q (7 cases, 4 non-mosaic,
and 3 mosaic); loss of 17p (7 cases, all mosaic); gain of whole
chromosome 7 (6 cases, 1 non-mosaic, and 5 mosaic) (Fig. 5).
Also, combinations of different aneuploidies were found,
such as both loss of chr18 and gain of chr20 (7 cases) and both
gains of chr13 and chr20 (4 cases). One case showed
chromothripsis on chromosome 13 and 15. No aneuploidies
were found in the normal samples.
Loss of heterozygosity
The slides used in our analysis combine array-CGH based
CNA detection with fully research-validated SNP content,
allowing confident and cost-effective CNA and loss of hetero-
zygosity (LOH) identification using a single array
(http://www.ogt.co.uk).
Analysisof thepercentageofhomozygotecalls for eachchro-
mosome indifferent samples highlighted averynarrowdistribu-
tion of percentages in the normal samples, ranging from 47 to
68% for all chromosomes, except for chromosome 16, the only
one whose distribution was comparable in both normal and tu-
moral samples. At variance, a larger distribution for all chromo-
somes, except for chromosome2,was found in tumoral samples.
The highest percentages were reached by chromosomes 12, 18,
4, and 15, whereas the highest average was that of chromosome
18, followed by chromosomes 5, 12, and 15 (Fig. 6).
Moreover, tumors showed a higher number of LOH re-
gions: in fact, only 4/15 normal samples showed LOH re-
gions, compared to 11/15 tumoral samples. We then selected
shared LOH region in normal and tumoral samples for further
analysis (Tables 4 and 5) and looked for copy neutral vs copy
gain LOH, being the first defined as an LOH accompanied by
disomy (cnLOH) and the latter an LOH accompanied by a
gain (copy gain LOH).
In normal tissues (samples 1 and 5), we found a copy-neutral
LOH on region Xp21.3 which contains the MAGEB18,
MAGEB6, andMAGEB5 genes, already reported in gain in two
other normal samples. In tumoral samples, the copy-neutral
LOH of 5q was shared by four cases, whereas shared LOHs of
chromosome 13q, coinciding with gains of these regions, indi-
cated that there are multiple copies of a single chromosome 13.
Finally, many samples shared LOH on Xq regions, several as
copy-neutral LOH and others as gains.
LOH corresponding to the copy number loss are not report-
ed because the concordance confirms deletion of interested
region.
Age and origin
Next, we analyzed a possible correlation between the age
of patients and CNAs. In normal samples, a decrease of
Table 2 Copy number alterations of tumoral and normal samples
Patient Normal aberrations Tumoral aberrations
Total Unique Shared Total Unique Shared
1 55 45 10 46 38 8
2 239 45 194 549 323 226
3 178 175 3 5 4 1
4 174 147 27 61 40 21
5 44 28 16 28 19 9
6 221 38 183 471 277 194
7 295 202 93 25 5 20
8 39 22 17 91 78 13
9 26 12 14 54 45 9
10 60 36 24 92 78 14
11 71 40 31 54 39 15
12 124 105 19 42 34 8
13 336 327 9 13 9 4
14 389 359 30 18 10 8
15 151 131 20 34 26 8
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CNAs in patients less than 65 years and a small increase
in those over 65 years was found, similar to those report-
ed in literature for tumoral samples (Fig. S3). At
variance in tumoral samples, a small increase under
65 years and a strong decrease over 65 years was
observed.
Fig. 5 Aneusomies and aneuploidies of chromosomes. Aneusomies and
aneuploidies of all chromosome arms are reported. The red square
indicates a non-mosaic gain (log2 ratio > 0.6), the pink square a mosaic
gain, and the green square a mosaic loss. Non-mosaic losses were not
found. The yellow square indicates a gain or a loss which includes 50–
80% of the chromosome arm; its absence indicates aberration larger than
80 % of the chromosome arm. Numbers reported in square expresses the
percentage of mosaicism
Table 3 Gains shared by at least
three samples Patients Gain/loss Genes
1, 2, 6 Gain 2p24.3 TRIB2 (oncogene that inactivates the transcription factor
C/EBPalpha and causes acute myelogenous leukemia)
2, 4, 6 Gain 3q29 MFI2 (cell-surface glycoprotein found on melanoma cells)
2, 4, 6 Gain 10q11.21 RET (Proto-oncogene. Diseases associated include familial
papillary thyroid carcinoma)
2, 4, 6 Gain 12q13.12 WNT1 (secreted signaling protein. Implicated in oncogenesis),
DDN (promotes apoptosis of kidney glomerular podocytes),
PRKAG1 (Regulatory subunit of the AMP-activated protein kinase)
1, 2, 6 Gain 21q22.12 RUNX1 (involved in the development of normal hematopoiesis.
Diseases associated include familial platelet disorder with
associated myeloid malignancy)
2, 4, 6 Gain Xq21.1 BRWD3 (chromatin-modifying function. Diseases associated
include chronic lymphocytic leukemia)
2, 4, 6 Gain Xq25 GRIA3 (receptor for glutamate)
2, 4, 6 Gain Xq25 XIAP (oncogene. Diseases associated include chronic neutrophilic leukemia)
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Moreover, we analyzed the origin of the samples and no-
ticed that normal and tumoral samples coming from one single
hospital showed a higher (but not statistically significant)
number of CNAs when compared to those coming from the
other centers (Fig. S4).
Discussion
Colorectal cancer is a highly heterogeneous disease and for
this reason, several genomic studies have been performed,
always analyzing in detail tumoral tissues using paired normal
tissues as reference for the tumoral counterpart. Only one pa-
per so far reported small gains at 19q and 20q in pooled nor-
mal tissues [9]. However, tumorigenic genetic lesions may be
already present also when the colonic tissue appear histolog-
ically normal, as suggested by the fact that in 10–20% of CRC
patients undergoing surgery with curative intent, a local recur-
rence successively occurs [10]. In strong support to this sug-
gestion, our data revealed for the first time an unexpected
frequency of genetic alterations in histologically normal co-
lonic tissue.
Accordingly, a very recent paper reported that transcrip-
tional profiles of paired normal samples could be of great
interest to better understand tumorigenesis mechanisms and
progression and identify potential therapeutic targets [14].
Our approach of performing CGH + SNPMicroarray on 15
paired histologically normal and tumoral samples allowed us
to find a high number of CNAs (average: 160) also in normal
colonic tissues. Our experiments showed excellent DLRS
values, so also mosaic CNAs were included in the study with
a good confidence. The possibility to detect mosaic CNAs
allows obtaining a representation of all sample subpopula-
tions, not only the most represented. For this reason, we found
a higher number of CNAs compared to some previous studies.
Mosaicism is defined as the occurrence of more than one
genetically diverse cell population in an organism arising from
a single fertilized egg [15]. Somatic mosaicism is a typical
condition of cancer, which is a mixture of different
subpopulations.
Fig. 6 Homozygote calls.
Percentage of homozygote calls
for each chromosome in normal
(blue) and tumoral (pink) samples
Table 5 Shared tumoral LOH















































































Table 4 Shared normal LOH
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In normal tissues many of affected genes involved or
claimed to be related to the tumorigenic process. For example,
the RUNX1 gene is considered a tumor suppressor gene in
myeloid neoplasm and was recently implicated in gastrointes-
tinal tumorigenesis, as a novel tumor-suppressor gene, which
maintains the balance between the intestinal stem/progenitor
cell population and epithelial differentiation [16]. Moreover,
genetic variations in RUNX1 were associated with colorectal
cancer risk [17].
Surprisingly, other tumor-suppressor genes, such as
PTCH1, DAB2IP, and WT1 were included in the gained re-
gions. Lower levels of PTCH1 mRNA were associated to
high-risk for metastasis [18], and aberrant methylation of
the PTCH1 promoter might be an early event of colon carci-
nogenesis [19], thus leaving the meaning of this gain worthy
to be further investigated. Notably, WT1 may act both as a
tumor suppressor or oncogene in different context [20]. In
colorectal adenocarcinoma, it has been reported to be
overexpressed [21] and its expression being a marker of poor
prognosis [22].
Traditionally, histologically normal tissue has been consid-
ered to be appropriate control for copy number studies as it
was not thought to have copy number aberrations: unexpect-
edly, instead, our data showed several oncogenes with copy
number gain. Overexpression of TRIB2, resulting from gene
amplification, has been described in lung cancer with a poten-
tial role in tumorigenesis [23]. RET promoter CpG island
methylation is associated with a poor prognosis in stage II
colorectal cancer [24], but RET fusion kinases has also been
identified [25]. Moreover, RET CNAs has been reported in
colorectal cancer [26]. Conversely, MPL, TRIB2, and ARAF
copy number gains have not previously been identified in
colon samples.
Finally, a mosaic gain on 8q24.21 containing MYC onco-
gene was found in two normal tissues, whose matched tumors
have an undifferentiated histotype. Since this gain has not
been found in other normal samples, we put forward the hy-
pothesis that it may be considered as an early alteration for this
tumor histotype.
As for normal tissues, also in tumoral samples, we found
CNAs containing RET gene, both in gain and in loss, as pre-
viously reported [26]. Also, a shared CNA containing APP
gene was both in gain and in loss in different samples.
Recently, increased expression of APP in several types of
cancer has been reported and it has been implicated in prolif-
eration and motility of advanced breast cancer [27]. To our
knowledge, this is the first time that APP CNAs is shown in
cancer.
We speculated that CNAs present only in tumors and diso-
mic in normal samples might have a possible role in tumor
progression. For example, in tumoral tissues, we found two
gained regions shared among at least three samples and con-
taining RBFOX1 and PCDH11Y genes. RBFOX1 belongs to a
family of evolutionarily conserved RNA-binding proteins and
regulates tissue-specific alternative splicing: deletion of
RBFOX1 has been already reported in colon tumors [28]
whereas copy number gain has been recently shown [29].
PCDH11Y instead plays a role during development of the
central nervous system, but it has also been reported to be
involved in prostate cancer progression [30]. Ours is the first
finding that PCDH11Y can be present in an altered copy num-
ber in CRC.
As already noted, the use in array-CGH analysis of
normal tissue as a reference for the corresponding tumor
allows uncovering only alterations not equally represented
in both tissue, leaving equal ones undetected and implying
that CNAs present in both tissues are more amplified in
the tumor; otherwise, they would have been scored as
disomic.
The identified gained regions contain TRIB2, MFI2, RET,
WNT1, DDN, PRKAG1, KMT2D, RUNX1, BRWD3, GRIA3,
and XIAP. All these genes are known to be involved, at least to
a certain degree, in different types of cancer: based on our
findings, we suggest that they might have a critical role also
in colorectal cancer onset and progression. Moreover, some of
these genes are target of current clinical trials for other types of
cancer, such as RET for non-small cell lung cancer, RUNX1
for leukemia, and XIAP for pancreatic and breast cancers
(http://clinicaltrials.gov, https://www.clinicaltrialsregister.eu),
so they could be interesting targets also for colorectal cancer
therapy.
Tumor copy number changes were also compared with
data of the Cancer Genomic Atlas (TCGA) database, where
all tumors were paired with normal tissue specimen which
could be blood/blood components, adjacent normal tissue,
or previously extracted germline DNA from blood [31]. In
the TCGA database, the most frequent aneuploidies are
gains of 1q, 7, 8 12q, 13q, and 20 and losses of 18 (66 %
of cases), 17 (56 %), followed by 1p, 4q, 5q, 8p, 14, 15,
20p, and 22q. Their data are in agreement with our results
as evident from Fig. 5 and the BResults^ section; especially
but not only for loss of 18 (66 % of our cases) and for loss
of 17p (46 %).
Loss of heterozygosity (LOH) occurs in a variety of
tumor types and is considered important for tumor progres-
sion. After the loss of one allele, the remaining allele can
be affected by somatic mutation or harbor a disease-prone
polymorphic variant [32]. It may happen that the lost re-
gion is replaced by an exact copy of the remaining chro-
mosome, resulting in the retention of two copies of genetic
information, but the loss of polymorphic differences [32];
in this case, we speak about copy-neutral LOH (also called
uniparental disomy).
Analysis of homozygote calls for each chromosome re-
vealed a strong difference in LOH regions between normal
and tumoral samples.
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Normal samples showed a lower number of LOH com-
pared to tumoral samples, being only two copy-neutral
LOHs shared between two different samples and located
in Xp21.3 and Xq26.2. The Xp21.3 region contains MAGE
family genes and interestingly, it is observed in copy num-
ber gain in two other normal samples. It is possible to
assume that this region may be subject to genomic alter-
ations in normal samples.
Copy-neutral LOH was found on chromosome 5q for
four tumoral cases. LOH of 5q was reported in ovarian
cancer, frequently accompanied by TP53 mutation [33]. It
was also observed in adenoma samples, suggesting that it
may play an important role in tumor initiation [34]. In 5q
region maps APC gene. APC LOH was found in four sam-
ples accompanied by copy number loss in two cases and
by the presence of two copies of the same regions in the
other two samples; this identifies a copy neutral LOH.
According to these data, a recent paper reported that most
of sporadic colorectal carcinomas with LOH for APC re-
turn to copy number neutrality with the duplication of the
remaining allele [35]. The copy gain LOH of 13q33.1 is
shared by three tumoral cases and indicates multiple copies
of the same allele.
CNAs were also compared with age of patients and sam-
ples’ origin. It was reported that humans are commonly
affected by somatic mosaicism for stochastic CNAs. The
rate of CNA occurrence may differ between cell types or
may be related to the age of individual cells [36]. We found
that the number of CNAs in normal tissues did not increase
linearly with the age as reported in literature for tumoral
samples [37], whereas our tumoral tissues showed an oppo-
site trend. These results could be explained by the fact that
our tumoral tissues were analyzed against the corresponding
normal sample and not against a reference. Analyzing the
origin of samples we found an increased, even though non-
significant, number of CNAs especially in normal samples
coming from a single hospital, leading us to hypothesize
that this increase may be due to a possible environmental
effect.
In conclusion, our approach to perform CGH + SNP
Microarray on paired normal and tumoral samples, allowed
us to uncover for the first time an unexpected frequency of
genetic alteration in normal colonic tissue from colon can-
cer patients, suggesting that (1) tumorigenic genetic lesions
are already present also when the colonic tissue appear
histologically normal; (2) the use in array-CGH studies of
normal samples as reference for the paired tumors can lead
to misrepresented genomic data, due the loss of identical
CNAs between the two samples; and (3) even available
array-CGH data may be incomplete or limited, especially
if used for the research of target molecules for personalized
therapy and for the possible correlation with clinical
outcome.
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